Piero et al. have estimated that CDX2 could be recognized as a biomarker for malignant tumors in clinical surveillance and prognosis due to the fact that patients with stage II and stage III colon cancer and a lack of CDX2 suffered neoplasm recurrence and subsequent death 11. This evidence concerns the gene CDX2 and colonic neoplasm.